AssetMark Inc’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

AssetMark Inc’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-13,538	Closed	-$590K	–	2024
2023 Q3	$590K	Buy	13,538 +5,717	+73%	+$204K	﹤0.01%	725
2023 Q2	$283K	Buy	7,821 +1,600	+26%	+$65.9K	﹤0.01%	794
2023 Q1	$231K	Buy	6,221 +902	+17%	+$40.6K	﹤0.01%	811
2022 Q4	$241K	Buy	5,319 +2,705	+103%	+$175K	﹤0.01%	793
2022 Q3	$183K	Buy	2,614 +1,008	+63%	+$74.6K	﹤0.01%	774
2022 Q2	$108K	Buy	1,606 +1,422	+773%	+$90.4K	﹤0.01%	813
2022 Q1	$15K	Buy	+184	New	+$18.8K	﹤0.01%	1133

Other funds holding MRTX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return

Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

AssetMark Inc's MRTX Position: Q4 2023 in Review

AssetMark Inc sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 13,538 shares — an estimated $590K sold.

AssetMark Inc first reported a position in MRTX in Q1 2022 and held it in 7 quarters. The position peaked at $590K in Q3 2023. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

AssetMark Inc reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
AssetMark Inc sold 13,538 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $590K.
AssetMark Inc first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2022 and held it in 7 quarters.
AssetMark Inc's Mirati Therapeutics, Inc. Common Stock position peaked at $590K in Q3 2023.
217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on AssetMark Inc's 13F filing for Q4 2023, filed 9 Feb 2024.